Levosimendan in cardiac surgery: A unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?

Anesthesia and Analgesia

Volumn 104, Issue 4, 2007, Pages 759-761

  Pagel, Paul S ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM SENSITIZER; CARDIAC MYOSIN; DOBUTAMINE; GLIBENCLAMIDE; LEVOSIMENDAN; MILRINONE; NORADRENALIN; PLACEBO; TROPONIN C; TROPONIN I;

ACTIN FILAMENT; ACUTE HEART INFARCTION; AORTA BALLOON; CALCIUM CELL LEVEL; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DILATATION; DESENSITIZATION; DIASTOLE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFORMANCE; HEART STROKE VOLUME; HEART SURGERY; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; LUNG CAPILLARY PRESSURE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SARCOLEMMA; STEADY STATE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES; VASCULAR SMOOTH MUSCLE;

ADRENERGIC BETA-AGONISTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; DOBUTAMINE; DRUG THERAPY, COMBINATION; HUMANS; HYDRAZONES; MILRINONE; MYOCARDIAL CONTRACTION; PERIOPERATIVE CARE; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34047255069     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000256864.75206.6d     Document Type: Editorial

References (33)

1. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556-69.
2. Tachibana H, Cheng HJ, Ukai T, et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005;288:H914-H922.
3. Scoote M, Williams AJ. Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun 2004;322:1286-309.
4. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
5. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart. The Task Force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
6. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
7. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995;27:2155-65.
8. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
9. Dernillis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest 2005;128:2633-9.
10. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
11. Pataricza J, Krassoi I, Hohn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-21.
12. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-25.
13. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997;283:375-83.
14. ATP channel opener. Eur J Pharmacol 2001; 428:311-14.
15. + channels and myocardial preconditioning. Circ Res 2000;87:431-3.
16. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a positive inotropic agent, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 2000;90:5-11.
17. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004;43:2177-82.
18. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005;45:704-8.
19. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 2006;96:694-700.
20. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohormonal effects of continuous infustion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
21. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patient with severe heart failure. Circulation 2000;102:2222-7.
22. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
23. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a controlled randomized clinical trial. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. JAMA 2002;287:1578-80.
24. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared to dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
25. Garcia-Gonzalez MJ, Dominguex-Rodriguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006;8:723-728.
26. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-6.
27. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
28. Labriola C, Siro-Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004;42:204-11.
29. Siirila-Waris K, Suojaranta-Ylinen R, Harjola VP. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005;19:345-9.
30. Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004;44:703-8.
31. De Hert SG, Lorsomradee S, Cromheecke S, et al. Effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104:766-73.
32. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-6.
33. Booth JV, Landolfo KP, Chesnut LC, et al. Acute depression of myocardial β-adrenergic receptor signaling during cardiopulmonary bypass: impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization Group. Anesthesiology 1998;89:602-11.